| 1 |
<div align="Center"><b>PLIVA major contributor at ICMAS-KO 6<br> |
| 2 |
</b></div> |
| 3 |
<br> |
| 4 |
<i>Bologna, 23-26 January 2002</i><br> |
| 5 |
<br> |
| 6 |
ICMAS-KO is the International Conference on the Macrolides, Azalides, Streptogramins, |
| 7 |
Ketolides & Oxazolidinones. It is the biggest international scientific |
| 8 |
event concerning macrolides and similar compounds. The purpose of the ICMAS |
| 9 |
conferences is to address current issues and future trends in the development |
| 10 |
and uses of these agents. The conference has been held every 2 years since |
| 11 |
1992. <br> |
| 12 |
PLIVA has been a sponsor of this event since 1996. In year 2002, PLIVA was |
| 13 |
one of the major contributors of the conference along with Pfizer Inc., Abbott |
| 14 |
Laboratories and Aventis.<br> |
| 15 |
<br> |
| 16 |
<div align="Center"><img src="/comm/stand-fJPG.jpg" alt="" width="300" height="225"> |
| 17 |
<br> |
| 18 |
<br> |
| 19 |
PLIVA exibition area at ICMASKO 6<br> |
| 20 |
<br> |
| 21 |
</div> |
| 22 |
<br> |
| 23 |
ICMAS-KO 6 was held in Bologna, Italy from January 23-26, 2002. It gathered |
| 24 |
about 800 delegates. The scientific program was organised in parallel sessions |
| 25 |
with the following content: |
| 26 |
<ul> |
| 27 |
<li>Plenary session</li> |
| 28 |
<ul> |
| 29 |
<li>New Microbial Targets for the MASKO Compounds</li> |
| 30 |
</ul> |
| 31 |
<li>5 workshop seminars:</li> |
| 32 |
<ul> |
| 33 |
<li>Evolving patterns of resistance mechanisms and prevalence,</li> |
| 34 |
</ul> |
| 35 |
<ul> |
| 36 |
<li>Issues in pharmacology and metabolism of MASKO compounds,</li> |
| 37 |
</ul> |
| 38 |
<ul> |
| 39 |
<li>In vitro activity of new MASKO compounds,</li> |
| 40 |
</ul> |
| 41 |
<ul> |
| 42 |
<li>Clinical infections: adult and paediatric,</li> |
| 43 |
</ul> |
| 44 |
<ul> |
| 45 |
<li>H.- pylori, other special pathogens and non-antibacterial effects |
| 46 |
of MASKO compounds)</li> |
| 47 |
</ul> |
| 48 |
<li>2 laboratory workshops</li> |
| 49 |
<ul> |
| 50 |
<li>Susceptibility testing of challenging microbes including streptococci, |
| 51 |
staphylococci, haemophillus and intracellular pathogens</li> |
| 52 |
</ul> |
| 53 |
<ul> |
| 54 |
<li>Specific techniques to detect and characterise resistance mechanisms</li> |
| 55 |
</ul> |
| 56 |
<li>3 company- sponsored symposia (Pfizer, Abbott and Aventis)</li> |
| 57 |
<li>Keynote lecture</li> |
| 58 |
<ul> |
| 59 |
<li>Countering the emergence of resistance to MASKO agents</li> |
| 60 |
</ul> |
| 61 |
</ul> |
| 62 |
<br> |
| 63 |
<br> |
| 64 |
A total of 196 posters were presented including 50 posters supported by PLIVA.<br> |
| 65 |
<br> |
| 66 |
<div align="Center"><img src="/comm/poster-f.JPG" alt="" width="300" height="225"> |
| 67 |
<br> |
| 68 |
<br> |
| 69 |
PLIVA has sponsored 50 poster presentations at ICMASKO 6<br> |
| 70 |
<br> |
| 71 |
</div> |
| 72 |
<br> |
| 73 |
The majority of PLIVA sponsored posters were discussed during workshop seminars |
| 74 |
particularly those once dealing with possible new indications.<br> |
| 75 |
<br> |
| 76 |
<div align="Center"><img src="/comm/petricekpredavanja-f.JPG" alt="" width="300" height="225"> |
| 77 |
<br> |
| 78 |
<br> |
| 79 |
The majority of PLIVA sopnsored posters were discussed during workshop seminars |
| 80 |
<br> |
| 81 |
<br> |
| 82 |
</div> |
| 83 |
<br> |
| 84 |
<i><u>Atherosclerosis</u></i><br> |
| 85 |
Croatian Azithromycin in Atherosclerosis Study (CROAATS) was one of two papers |
| 86 |
presented in that field. The role of azithromycin in the secondary prevention |
| 87 |
of adverse cardiovascular events in C. pneumoniae-positive post-myocardial |
| 88 |
infarction patients is still to be defined. Some data from Azithromycin Coronary |
| 89 |
Events Study (ACES) were also presented but the study is to be finished |
| 90 |
in December 2003 and for the time being the presented results are inconclusive.<br> |
| 91 |
<br> |
| 92 |
<i><u>H.pylori infections</u></i><br> |
| 93 |
Four presented H. pylori studies were considered to be very interesting because |
| 94 |
up to know limited data was available about azithromycin therapy in the treatment |
| 95 |
of H.pylori infection. According to the presented results azithromycin, as |
| 96 |
a part of triple therapy, appears to be of equal clinical and bacteriological |
| 97 |
efficacy as triple therapies containing clarithromycin .The advantage of |
| 98 |
azithromycin is in simple and short dosage regimen.<br> |
| 99 |
<br> |
| 100 |
<u><i>Other infections</i></u><br> |
| 101 |
The posters dealing with new possible azithromycin indications as acne and |
| 102 |
chlamydial conjunctivitis also took part in workshop seminars. Single dose |
| 103 |
of azithromycin was as effective as standard regimen of doxycycline twice |
| 104 |
daily for 10 days in the treatment of chlamydial conjunctivitis. The preliminary |
| 105 |
results of acne study support earlier reports on the safety and efficacy |
| 106 |
of azithromycin pulse therapy in acne treatment. The final findings of the |
| 107 |
study will be used as a basis for planning a pivotal comparative trial in |
| 108 |
acne patients. <br> |
| 109 |
The case report of azithromycin in the therapy of actinomycosis was particularly |
| 110 |
attractive because of completely new indication area and new dosage regimen |
| 111 |
(prolonged azithromycin treatment) as well as gathered safety data.<br> |
| 112 |
According to the presented papers azithromycin seems to be effective therapy |
| 113 |
in the treatment of cat scratch disease and shows encouraging results in |
| 114 |
the treatment of respiratory infections in oncology patients.<br> |
| 115 |
<br> |
| 116 |
<br> |
| 117 |
<b>PLIVA satellite symposium: Sumamed – today and tomorrow<br> |
| 118 |
<br> |
| 119 |
</b> |
| 120 |
<div align="Center"><img src="/comm/sastanaksledja-f.JPG" alt="" width="300" height="225"> |
| 121 |
<br> |
| 122 |
<br> |
| 123 |
Sumamed today and tomorrow <br> |
| 124 |
</div> |
| 125 |
<br> |
| 126 |
<br> |
| 127 |
On January 26 all PLIVA sponsored participants were invited to the PLIVA |
| 128 |
meeting with following program: |
| 129 |
<ol> |
| 130 |
<li>PLIVA today & tomorrow (Mr. Gerard Cole)</li> |
| 131 |
<li>Mechanisms of macrolide resistance (Viktorija Tomic, MD)</li> |
| 132 |
<li>Antimicrobial resistance in Russia (Sergei V. Sidorenko, MD. PhD)</li> |
| 133 |
<li>The position of macrolides in the treatment of respiratory tract infections |
| 134 |
(Bruno Barsic, MD. PhD)</li> |
| 135 |
<li>Azithromycin - Future perspectives (Artur Banaszak, MD)</li> |
| 136 |
</ol> |
| 137 |
The main issue of the meeting was the problem of the antibacterial resistance |
| 138 |
and its impact on clinical practice. As it was mentioned in report of Abbott |
| 139 |
symposium the general impression is that obvious contradiction in results |
| 140 |
exist. The results from clinical studies from early and late 90`s show that |
| 141 |
there is no change in macrolide efficacy in the treatment of RTI in the last |
| 142 |
decate despite reported dramatic increase of laboratory resistance. It opens |
| 143 |
lot of questions: is resistance rate overestimated, are MIC breakpoints well |
| 144 |
established - should they be changed, what about influence on immune |
| 145 |
system?<br> |
| 146 |
<br> |
| 147 |
The final conclusions of the meeting were: |
| 148 |
<ul> |
| 149 |
<li>Susceptibility testing is performed by different methods – broth microdilution, |
| 150 |
agar dilution, disk diffusion, E test, and resistance gene determination |
| 151 |
with molecular methods. Published data about resistance are not always based |
| 152 |
on standardised methods and does not take in account influence of medium, |
| 153 |
incubation atmosphere, length of incubation, inoculum size and colony age |
| 154 |
when interpreting results and that is why are sometimes missleading.</li> |
| 155 |
<li>In-vitro and. in-vivo conditions are dfferent (immune response |
| 156 |
of the host)</li> |
| 157 |
<li>Pharmacokinetic/pharmacodynamic parameters of the antimicrobial infuence |
| 158 |
the clinical outcome</li> |
| 159 |
<li>Factors associated with individual patients should be also taken into |
| 160 |
account::</li> |
| 161 |
<ul> |
| 162 |
<li>outpatient/inpatient, compliance</li> |
| 163 |
</ul> |
| 164 |
<ul> |
| 165 |
<li>age, comorbidity, clinical status</li> |
| 166 |
</ul> |
| 167 |
<ul> |
| 168 |
<li>site of infection, intensity of infection.</li> |
| 169 |
</ul> |
| 170 |
</ul> |
Parent Directory
| 
Revision Log